Retrospective Cohort Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Infect Dis. Sep 29, 2022; 12(2): 50-60
Published online Sep 29, 2022. doi: 10.5495/wjcid.v12.i2.50
Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota
Bakir Dzananovic, Mark Williamson, Casmiar Nwaigwe, Chittaranjan Routray
Bakir Dzananovic, Department of Medicine, Idaho College of Osteopathic Medicine, Meridian, ID 83642, United States
Mark Williamson, Department of Biostatistics, Epidemiology and Research Design Core, University of North Dakota, Grand Forks, ND 58202, United States
Casmiar Nwaigwe, Department of Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Minot, ND 58701, United States
Chittaranjan Routray, Family Medicine, University of North Dakota School of Medicine and Health Sciences, Minot, ND 58701, United States
Chittaranjan Routray, Department of Internal Medicine, Trinity Health, Minot, ND 58701, United States
Author contributions: Routray C was the principal investigator and designed the study; Nwaigwe C was the co-investigator, participating in study design and revision of manuscript for intellectual content; Dzananovic B helped with data acquisition, analysis and initial manuscript writing; Williamson M performed the biostatistical analysis and interpretation of the data.
Supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award, No. U54GM128729.
Institutional review board statement: Institutional review board statement: This study was reviewed and approved by the Trinity Hospital, Institutional Review Board Committee.
Informed consent statement: Obtaining informed consent was waived by the IRB committee since this was a retrospective cohort study.
Conflict-of-interest statement: There are no conflict of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE statement- checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chittaranjan Routray, MD, Clinical Assistant Professor (Honorary), Family Medicine, University of North Dakota School of Medicine and Health Sciences, Minot, ND 58701, United States. routrayc@gmail.com
Received: June 18, 2022
Peer-review started: June 18, 2022
First decision: July 14, 2022
Revised: August 2, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: September 29, 2022
Core Tip

Core Tip: We intended to study an immunologic marker to predict the need for advanced oxygen supplement system and clinical outcome in order to support our hospital crisis management system during the peak of the pandemic. Our study demonstrated that presence of anti-nucleocapsid-IgG (IgG-N) against severe acute respiratory syndrome coronavirus 2 infection had no impact on the clinical outcome or disease severity in hospitalized coronavirus disease 2019 (COVID-19) patients. We did not find a correlation of statistical significance to use IgG-N as a biomarker to predict clinical outcome in COVID-19 patients admitted to a community hospital in North Dakota.